As of 2026-03-27, the EV/EBITDA ratio of BridgeBio Pharma Inc (BBIO) is -35.73. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. BridgeBio's latest enterprise value is 16,207.74 mil USD. BridgeBio's TTM EBITDA according to its financial statements is -453.57 mil USD. Dividing these 2 quantities gives us the above BridgeBio EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.0x - 13.2x | 9.8x |
| Forward P/E multiples | 6.4x - 9.2x | 7.8x |
| Fair Price | (29.70) - (32.50) | (31.56) |
| Upside | -140.9% - -144.8% | -143.5% |
| Date | EV/EBITDA |
| 2026-03-24 | -34.00 |
| 2026-03-23 | -34.46 |
| 2026-03-20 | -34.01 |
| 2026-03-19 | -34.66 |
| 2026-03-18 | -34.68 |
| 2026-03-17 | -35.03 |
| 2026-03-16 | -35.07 |
| 2026-03-13 | -34.38 |
| 2026-03-12 | -33.77 |
| 2026-03-11 | -35.22 |
| 2026-03-10 | -36.48 |
| 2026-03-09 | -32.77 |
| 2026-03-06 | -32.65 |
| 2026-03-05 | -32.99 |
| 2026-03-04 | -33.15 |
| 2026-03-03 | -32.29 |
| 2026-03-02 | -32.71 |
| 2026-02-27 | -33.13 |
| 2026-02-26 | -33.61 |
| 2026-02-25 | -33.15 |
| 2026-02-24 | -33.91 |
| 2026-02-23 | -33.74 |
| 2026-02-20 | -33.84 |
| 2026-02-19 | -34.94 |
| 2026-02-18 | -36.31 |
| 2026-02-17 | -37.13 |
| 2026-02-13 | -36.87 |
| 2026-02-12 | -37.22 |
| 2026-02-11 | -36.05 |
| 2026-02-10 | -35.69 |
| 2026-02-09 | -35.61 |
| 2026-02-06 | -33.80 |
| 2026-02-05 | -31.95 |
| 2026-02-04 | -36.85 |
| 2026-02-03 | -38.13 |
| 2026-02-02 | -38.15 |
| 2026-01-30 | -37.74 |
| 2026-01-29 | -38.52 |
| 2026-01-28 | -37.83 |
| 2026-01-27 | -37.99 |
| 2026-01-26 | -37.97 |
| 2026-01-23 | -37.99 |
| 2026-01-22 | -38.87 |
| 2026-01-21 | -38.11 |
| 2026-01-20 | -37.70 |
| 2026-01-16 | -37.31 |
| 2026-01-15 | -37.31 |
| 2026-01-14 | -38.01 |
| 2026-01-13 | -38.52 |
| 2026-01-12 | -37.55 |